Seffalair Spiromax Európai Unió - magyar - EMA (European Medicines Agency)

seffalair spiromax

teva b.v. - fluticasone propionate, salmeterol xinafoate - asztma - gyógyszerek obstruktív légúti betegségek, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.